Orthofix Medical Past Earnings Performance
Past criteria checks 0/6
Orthofix Medical's earnings have been declining at an average annual rate of -27%, while the Medical Equipment industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 15.8% per year.
Key information
-26.98%
Earnings growth rate
-14.69%
EPS growth rate
| Medical Equipment Industry Growth | 8.90% |
| Revenue growth rate | 15.76% |
| Return on equity | -13.79% |
| Net Margin | -7.27% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jul 01
OFIX: CMS Reimbursement Reset Will Shape 2028 Profitability And Margin Outlook
Analysts have trimmed the fair value estimate for Orthofix Medical to $12.00 from $14.00, reflecting lower long term revenue growth and profit margin assumptions after recent CMS reimbursement changes to the company’s non invasive bone growth stimulator portfolio. Analyst Commentary on Orthofix Medical Recent Street research around Orthofix Medical centers on the impact of CMS reimbursement changes and the FDA reclassification of non invasive bone growth stimulators, with analysts revisiting their models and fair value assumptions.
Narrative Update • Jun 17
OFIX: CMS Reimbursement Reset And FY26 Guide Will Drive Multi Year Repricing
Orthofix Medical's analyst price targets have reset lower toward $15, with analysts citing the recent CMS reimbursement cuts for non-invasive bone growth stimulators as the main reason for trimming their expectations. Analyst Commentary Recent research on Orthofix Medical highlights a reset in expectations around reimbursement for non-invasive bone growth stimulators, with analysts reassessing both the risk to earnings and the potential for the stock to recover as investors gain clarity on the new CMS framework.Narrative Update • Jun 03
OFIX: CMS Reimbursement Reset And 2026 Guidance Will Support Multi Year Repricing
Orthofix Medical's updated fair value estimate has been reduced to $15.00 from $17.25, as analysts factor in lower projected revenue growth, a slightly higher discount rate, and Street research highlighting the impact of recent CMS reimbursement changes on the company's non-invasive bone growth stimulator portfolio. Analyst Commentary Street research on Orthofix Medical reflects a mix of cautious and constructive views following the recent CMS reimbursement updates and the company's revised long-term outlook.Narrative Update • May 16
OFIX: Later Margin Timeline And 2026 Outlook Will Support Multi Year Repricing
Narrative Update: Orthofix Medical Analysts have trimmed their average price targets for Orthofix Medical by a few dollars into a range of about $17 to $20 after revising models for Q4 results and updated margin timelines. This aligns with a fair value estimate of $17.25 and modest adjustments to growth, discount rate, margin assumptions and future P/E expectations.Analysis Article • May 08
US$17.25: That's What Analysts Think Orthofix Medical Inc. (NASDAQ:OFIX) Is Worth After Its Latest Results
It's been a good week for Orthofix Medical Inc. ( NASDAQ:OFIX ) shareholders, because the company has just released its...Narrative Update • Apr 24
OFIX: Later Margin Timeline And 2026 Guidance Will Support Multi Year Repricing
Narrative Update on Orthofix Medical The analyst price target for Orthofix Medical edges down to $17.25, with analysts pointing to refreshed Q4 based models, updated 2026 guidance, and a longer adjusted EBITDA margin timeline as key reasons for the adjustment. Analyst Commentary Recent Street research on Orthofix Medical shows a cluster of target price reductions, driven mainly by refreshed Q4 models, updated 2026 guidance, and a longer path to the company’s adjusted EBITDA margin goals.Narrative Update • Apr 10
OFIX: Extended EBITDA Timeline Will Support 2028 Profitability And Margin Reassessment
Orthofix Medical's updated analyst price targets cluster in the mid to high teens, with several firms trimming their views to a range of about $17 to $20 as analysts refresh models for recent Q4 results, revised 2026 guidance, and a longer timeline for margin expansion. Analyst Commentary Recent Street research on Orthofix reflects a more cautious tone, even as analysts refresh models following Q4 results and updated 2026 guidance.Narrative Update • Mar 27
OFIX: Longer EBITDA Timeline Will Set Up 2028 Profitability Reassessment
Orthofix Medical’s latest narrative update keeps fair value unchanged at $14.00, as analysts temper price targets to a $17 to $20 range after revising models around Q4 results, updated 2026 guidance, and a longer timeline to reach adjusted EBITDA margin goals. Analyst Commentary Recent research updates show that bearish analysts are trimming expectations for Orthofix Medical, even as they maintain generally constructive views on the business.Narrative Update • Mar 13
OFIX: Later Margin Timeline And 2026 Outlook Will Support Multi Year Repricing
Analysts have trimmed their fair value estimate for Orthofix Medical to $17.25 from $19.25, reflecting recent reductions in Street price targets as models are refreshed following Q4 results and updated long term guidance. Analyst Commentary Street research on Orthofix Medical has recently focused on recalibrating valuation targets and timing assumptions following Q4 results and updated long term guidance.Narrative Update • Feb 26
OFIX: Later Margin Timeline Will Support Bullish Multi Year Earnings Repricing
Analysts have lowered their price target on Orthofix Medical from $22.55 to $19.25. This change reflects updated views on the timing of margin improvement and valuation metrics, following recent research that indicates a later adjusted EBITDA margin target and a more neutral stance on the shares.Narrative Update • Feb 11
OFIX: Neutral Outlook Will Weigh Execution Risks Against Margin And Multiple Assumptions
Analysts have maintained their $14.00 price target on Orthofix Medical, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that are consistent with a recently initiated neutral view on the stock. Analyst Commentary Bearish analysts are broadly signaling a wait and see stance on Orthofix Medical, with the neutral initiation and maintained $14.00 price target reflecting a more cautious setup rather than a clear bullish call.Narrative Update • Jan 28
OFIX: Neutral Spine Platform Outlook Will Balance Execution Risk And Margin Potential
Analysts have trimmed their price target on Orthofix Medical to US$14.00 from US$18.00. This reflects updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations following recent research, including a neutral initiation at TD Cowen.Narrative Update • Jan 07
OFIX: Spine Platform Execution Will Support Future Margin Expansion And Earnings Power
Analysts have adjusted their outlook on Orthofix Medical, highlighting a Street price target of US$22 and citing expectations for "profitable growth at an attractive valuation" as investors wait for longer term benefits from the 7D FLASH spine platform. Analyst Commentary The current Street view on Orthofix Medical centers on a US$22 price target that reflects confidence in the company’s ability to deliver profitable growth while investors wait for potential benefits tied to the 7D FLASH spine platform and broader spine industry trends.Narrative Update • Dec 14
OFIX: Spine Technology Tailwinds Will Support Margin Expansion And Earnings Power
Analysts have raised their fair value estimate for Orthofix Medical to $18.00 from $17.00, citing expectations for slightly faster revenue growth, improved profit margins, and a still attractive valuation supported by recent Buy-rated Street research. Analyst Commentary Recent Street commentary has highlighted a constructive long term outlook for Orthofix Medical, with the latest research emphasizing profitable growth potential supported by emerging technology tailwinds in the spine segment.Analysis Article • Nov 07
Here's What Analysts Are Forecasting For Orthofix Medical Inc. (NASDAQ:OFIX) After Its Third-Quarter Results
Last week, you might have seen that Orthofix Medical Inc. ( NASDAQ:OFIX ) released its third-quarter result to the...Seeking Alpha • Aug 07
Orthofix Medical: Compelling Valuation Supported By Insider Purchases
Summary We increased our Orthofix Medical position after a sharp sell-off, viewing the valuation as compelling, especially with insider and major shareholder buying. Orthofix’s integration of Seaspine is nearly complete, financials are strong, and management reaffirmed positive free cash flow and EBITDA margin improvement targets for 2025-2027. Recent revenue guidance cut was due to one-time factors, not long-term weakness; new product launches and FDA clearances support future growth across all segments. At just 6.4x 2025 EBITDA, OFIX trades at a deep discount to peers; our $18.50 price target offers 65.9% upside, with further potential if margin goals are met. Read the full article on Seeking Alpha
New Narrative • Mar 26
7D FLASH And New Products Will Revitalize US Orthopedics Market
Orthofix's investments in enabling technologies and innovative products are set to enhance market penetration and competitive advantage, driving revenue growth.Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Orthofix Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 825 | -60 | 556 | 61 |
| 31 Dec 25 | 822 | -92 | 554 | 66 |
| 30 Sep 25 | 818 | -119 | 554 | 69 |
| 30 Jun 25 | 809 | -124 | 536 | 72 |
| 31 Mar 25 | 805 | -143 | 534 | 74 |
| 31 Dec 24 | 799 | -126 | 533 | 74 |
| 30 Sep 24 | 784 | -119 | 527 | 74 |
| 30 Jun 24 | 772 | -120 | 520 | 75 |
| 31 Mar 24 | 760 | -126 | 519 | 76 |
| 31 Dec 23 | 747 | -151 | 530 | 80 |
| 30 Sep 23 | 668 | -136 | 483 | 74 |
| 30 Jun 23 | 598 | -118 | 436 | 68 |
| 31 Mar 23 | 529 | -76 | 378 | 61 |
| 31 Dec 22 | 461 | -20 | 309 | 49 |
| 30 Sep 22 | 464 | -45 | 299 | 49 |
| 30 Jun 22 | 462 | -37 | 297 | 50 |
| 31 Mar 22 | 465 | -37 | 297 | 50 |
| 31 Dec 21 | 464 | -38 | 291 | 50 |
| 30 Sep 21 | 457 | -15 | 288 | 47 |
| 30 Jun 21 | 456 | -8 | 285 | 44 |
| 31 Mar 21 | 407 | -29 | 267 | 40 |
| 31 Dec 20 | 407 | 3 | 272 | 39 |
| 30 Sep 20 | 410 | 24 | 277 | 37 |
| 30 Jun 20 | 413 | -22 | 284 | 35 |
| 31 Mar 20 | 456 | -4 | 304 | 35 |
| 31 Dec 19 | 460 | -28 | 309 | 35 |
| 30 Sep 19 | 460 | -31 | 302 | 35 |
| 30 Jun 19 | 458 | 8 | 298 | 37 |
| 31 Mar 19 | 453 | 9 | 291 | 36 |
| 31 Dec 18 | 453 | 14 | 289 | 33 |
| 30 Sep 18 | 449 | 6 | 284 | 33 |
| 30 Jun 18 | 442 | 11 | 278 | 30 |
| 31 Mar 18 | 440 | 15 | 277 | 29 |
| 31 Dec 17 | 434 | 7 | 276 | 30 |
| 30 Sep 17 | 425 | 1 | 274 | 29 |
| 30 Jun 17 | 419 | 8 | 272 | 29 |
| 31 Mar 17 | 414 | -3 | 266 | 29 |
| 31 Dec 16 | 410 | 3 | 261 | 29 |
| 30 Sep 16 | 406 | 11 | 254 | 29 |
| 30 Jun 16 | 409 | 0 | 256 | 29 |
| 31 Mar 16 | 405 | 10 | 259 | 28 |
| 31 Dec 15 | 396 | -2 | 274 | 26 |
| 30 Sep 15 | 392 | -10 | 274 | 25 |
Quality Earnings: OFIX is currently unprofitable.
Growing Profit Margin: OFIX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OFIX is unprofitable, and losses have increased over the past 5 years at a rate of 27% per year.
Accelerating Growth: Unable to compare OFIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OFIX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.8%).
Return on Equity
High ROE: OFIX has a negative Return on Equity (-13.79%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 06:00 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orthofix Medical Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Spencer Nam | Brean Capital Historical (Janney Montgomery) |
| Caitlin Cronin | Canaccord Genuity |